Navigation Links
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Date:1/4/2008

ed Mr. Sekhri. "We are extremely pleased to have Matt join us as a member of our senior management team and believe he will contribute greatly to our efforts of building a pipeline of products aligned with our corporate strategy."

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation, and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe ulcerative colitis in the first quarter of 2007. Cerimon's topical patch formulation of diclofenac sodium completed a Phase I study in the fourth quarter of 2007. This study will rapidly be followed by two Phase II/III studies for the treatment of acute musculoskeletal pain.

The Company is well-financed, having closed a $70 million Series A financing in late 2005 with premier investors including MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Pa., Sept. 7, 2011 Tengion, Inc (NASDAQ: ... Brian Davis, Vice President and Chief Financial Officer of Tengion, ... Healthcare Conference on Tuesday, September 13, 2011, at 1:35 pm ... can be accessed under "Calendar of Events" in the Investors ...
... 2011 The Journal of Cell Biology ... pleased to announce their next enhancement to the JCB ... published scientific image data. Starting today, data from genome-wide ... with papers published in JCB. HCS data are increasingly ...
... 7, 2011 Debiopharm Group™ ... focuses on serious medical conditions and particularly ... privately-held, biopharmaceutical company dedicated to the discovery ... cancer, have entered into an exclusive worldwide ...
Cached Biology Technology:Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference 2Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Genome-Wide Screens 2Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Genome-Wide Screens 3Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 2Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 3
(Date:4/16/2014)... ,, Sometimes known as Kennedy,s disease, spinal and bulbar muscular ... slowly progressive muscle weakness and atrophy. Researchers have long considered ... the cells in the spinal cord and brainstem that ... in the April 16, 2014 online issue of Neuron ...
(Date:4/16/2014)... thoughts and feelings are the result of neurons talking ... of the conversations might not be all that private. Brain ... even participating in, some of those discussions. But a new ... part of the time specifically, when the neurons get ...
(Date:4/16/2014)... Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... Freiburg have discovered the receptor responsible for smuggling the toxin ... The TpeL toxin, which is formed by C. perfringens ... It is very similar to the toxins of many other ...
Breaking Biology News(10 mins):Mutant protein in muscle linked to neuromuscular disorder 2Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3Gate for bacterial toxins found 2
... the president of Conservation International and a global leader ... Medal from the Harvard Museum of Natural History. ... who has written more than 500 scientific and popular ... has described 11 species new to science, had seven ...
... Scientists at UC Santa Barbara have made a significant discovery ... They explain nature,s way of controlling whether these cells will ... a liver, or any other part of the human body. ... the journal Cell . The scientists say the ...
... a successful second funding period, the first three DFG ... for another four years. This decision was made by ... Research Foundation) at its spring session in Bonn. As ... in the Earth System" in Bremen, "The Center for ...
Cached Biology News:Scientists shed light on inner workings of human embryonic stem cells 2Scientists shed light on inner workings of human embryonic stem cells 3The first DFG research centers to be funded for another four years 2The first DFG research centers to be funded for another four years 3The first DFG research centers to be funded for another four years 4
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
...
... a dedicated system for SFC and SFE ... of HPLC instrumentation. JASCO has recently added ... of the system: ,- The PU-1580-CO2 delivery ... procedures using carbon dioxide as the mobile ...
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
Biology Products: